Erratum to: phase I study of neoadjuvant chemoradiotherapy with S-1 plus biweekly cisplatin for advanced gastric cancer patients with lymph node metastasis -KOGC04-
After the publication of this work [1], we noted that owing to an inadvertent mistake, the description of the chemotherapy schedule shown in the Methods was different from that shown in the Abstract and the duration of S-1 treatment in the initial chemoradiotherapy was inadequately described in Figure 1. Therefore, Methods and Figure 1 were modified accordingly.
Figure 1
Chemoradiotherapy consisted of combination chemotherapy with S-1, biweekly cisplatin, and fractionated radiation therapy.
×
In the “Chemoradiotherapy” section in the Methods, the 1st and 3rd paragraphs should read as follows:
Anzeige
“The chemoradiotherapy protocol consisted of administration of S-1 plus biweekly cisplatin and radiation (Figure 1). The initial chemoradiotherapy schedule was for 6 weeks: S-1 was orally administered twice daily from the evening of day 1 to the morning of day 15, and the total dose was based on the patient’s body surface area (BSA), as follows: <1.25 m2, 80 mg; 1.25–1.5 m2, 100 mg; and >1.5 m2, 120 mg. An escalating dose of cisplatin was administered by infusion over 1 h on days 1 and 15 without infusional hydration. The starting dose (level 1) of cisplatin was 15 mg/m2, the second dose (level 2) was 20 mg/m2, and the third dose (level 3) was 25 mg/m2.”
“After initial chemoradiotherapy, one cycle of combination chemotherapy with S-1 plus biweekly cisplatin was delivered. This consisted of 42 days of S-1 administered from the evening of day 1 to the morning of day 29 and of cisplatin administered on days 1, 15, and 29.”In “Figure 1,” based on the description in the manuscript, the duration of S-1 treatment in the initial chemoradiotherapy was revised to 1–15 days from 1–22 days (Figure 1).
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.
The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
Erratum to: phase I study of neoadjuvant chemoradiotherapy with S-1 plus biweekly cisplatin for advanced gastric cancer patients with lymph node metastasis -KOGC04-
Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.
Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.
Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.
Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.
Update Onkologie
Bestellen Sie unseren Fach-Newsletterund bleiben Sie gut informiert.
